Estimation of tamoxifen metabolite concentrations in the blood of breast cancer patients through CYP2D6 genotype activity score

• Published in: Breast cancer research and treatment Vol. 133; no. 2; pp. 677 - 683
• Main Authors: Wu, Alan H. B., Lorizio, Wendy, Tchu, Simone, Lynch, Kara, Gerona, Roy, Ji, Wuyang, Ruan, Weiming, Ruddy, Kathryn J., Desantis, Stephen D., Burstein, Harold J., Ziv, Elad
• Format: Journal Article
• Language: English
• Published: Boston Springer US 01.06.2012; Springer; Springer Nature B.V
• Subjects: Adjuvant treatment; Adult; Algorithms; Analysis; Antineoplastic Agents, Hormonal - metabolism; Biological and medical sciences; Body mass index; Breast cancer; Breast Neoplasms - blood; Breast Neoplasms - genetics; Breast Neoplasms - metabolism; Cancer; Cancer patients; Cancer research; Cancer therapies; Care and treatment; Clinical Trial; Cohort Studies; Cytochrome P-450; Cytochrome P-450 CYP2D6 - genetics; Drug therapy; Female; Genetic aspects; Genotype; Genotype & phenotype; Gynecology. Andrology. Obstetrics; Health aspects; Humans; Mammary gland diseases; Medical sciences; Medicine; Medicine & Public Health; Metabolites; Middle Aged; Oncology; Tamoxifen; Tamoxifen - analogs & derivatives; Tamoxifen - blood; Tamoxifen - metabolism; Tumors; Genotype; Endoxifen; Breast cancer; Tamoxifen; CYP2D6; Activity score; Antineoplastic agent; Biological fluid; Breast disease; Isozyme; Metabolite; Antiestrogen; Antihormone; Blood; Selective estrogen receptor modulator; Non steroid compound; Human; Enzyme; Cytochrome P450; Estimation; Patient; Malignant tumor; Concentration; Biological activity; Tamoxifene; Mammary gland diseases; Score; Cancer

Tamoxifen, a prodrug used for adjuvant breast cancer therapy, requires conversion to the active metabolite endoxifen through CYP 2D6. We aimed to construct an algorithm to predict endoxifen concentrations based on a patient’s CYP 2D6 genotype, demographic factors, and co-medication use. Eighty-eight...